N/A N=211 Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®
Type 1 Diabetes
Primary: Primary Safety Endpoint - Change in HbA1c — -0.1; -0.4 percentage of HbA1c — p=0.133
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=108 A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Gastrointestinal Stromal Tumor(GIST)
Primary: Progression-free Survival (PFS) — 10.3; 8.3 months
Phase 2 N=16 Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Metastatic Melanoma · Stage IIIB Cutaneous Melanoma AJCC v7 · Stage IIIC Cutaneous Melanoma AJCC v7
Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants
N/A N=188 Tailored Motivational Interviewing Implementation-Effectiveness Trial in Multidisciplinary Adolescent HIV Care Settings
HIV Infections · Adolescent Development · Care Eliciting Behavior
Primary: Raw Average: 12-Item Motivational Interviewing (MI) Coach Rating Scale (CRS) — 2.72; 2.50; 1.99; 2.32 Units on a scale
Phase 2 N=75 Safety and Efficacy of XT-150 for Facet Joint Osteoarthritis Pain
Facet Joint Pain · Back Pain · Inflammation
Primary: Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs — 11; 12; 14; 14 Participants
N/A N=87 Parent-Led Cognitive-Behavioral Teletherapy for Anxiety in Youth With ASD
Cognitive Behavioral Therapy · Autism Spectrum Disorder · Anxiety Disorders
Primary: 6-item Pediatric Anxiety Rating Scale — 11.35; 10.26 Score on a scale
Phase 2 N=374 NDV-HXP-S Vaccine Clinical Trial (COVIVAC)
COVID-19
Primary: Percentage of Participants With Local and Systemic Solicited AEs by Severity During the First 7 Days After Each Vaccination. — 78.2; 80.0; 88.0; 77.4 percent of…
N/A N=163 Remote School-Home Program to Improve Youth Attention and Behavior in Mexican Students
ADHD · Oppositional Defiant Disorder
Primary: Change in Child Symptom Inventory-4 (CSI-4) Parent Checklist ADHD Combined Type Symptom Severity Score — 1.73; 1.90; 0.96; 1.43 score on a scale
N/A N=71 The iTAP Study for Veterans
Insomnia · Alcohol; Harmful Use
Primary: Recruitment — 71 Participants
Phase 3 N=384 Rapid Evaluation of Innovative Intervention Components to Maximize the Health Benefits of Behavioral Obesity Treatment Delivered Online: An Application of Multiphase Optimization Strategy
Overweight and Obesity
Primary: Weight Change (Percent of Initial Body Weight) From Baseline to Month 12, Main Effect of Time — -5.8 percent of initial body weight — p=<.001
Phase 2 N=17 Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft
Limbal Stem Cell Deficiency
Primary: Primary Safety Events of Interest — 1; 0; 0; 0 Participants
Phase 1 N=10 Weight Management Program for Patients With First Episode Psychosis
Diet, Healthy · Psychotic Disorders
Primary: Weight — -6; -3; -5; -4 Lbs
Phase 1 N=25 Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Infusion of XTMAB-16 in Healthy Adult Participants
Healthy Participants
Primary: Participant With Treatment Emergent Adverse Events (TEAEs) — 2; 3; 1 Participants
Early Phase 1 N=28 Fingolimod as a Treatment of Cerebral Edema After Intracerebral Hemorrhage
Intracerebral Hemorrhage · Cerebral Edema · Stroke Hemorrhagic
Primary: Number of Participants With Clinically Significant Cardiac Events — 3; 0; 0 Participants — p=0.0427
N/A N=48 Intelligent and Adaptive Control Applied to Powered Walkers
Cerebral Palsy
Primary: Metabolic Cost (Oxygen Consumption) — 11.0; 12.7; 7.0; 9.4 J/kg — p=< 0.001